Table 2.
Effect of 5 days of oral administration of 300 mg·kg−1·day−1 Ro11-1464 on body and liver weight, liver lipids and plasma levels of liver enzymes
| Vehicle (n = 10) | Ro 11-1464 (n = 10) | % of control | |
|---|---|---|---|
| BW day 0 (g) | 30.7 ± 3.1 | 30.7 ± 2.1 | |
| BW day 5 (g) | 27.7 ± 2.7 | 27.0 ± 1.9 | |
| Δ BW (g) | −3.6 ± 2.2 | −4.0 ± 1.2 | |
| Liver wt day 5 (g) | 1.16 ± 0.18 | 1.55 ± 0.24* | 133.6 |
| Liver TG (mg g−1 ww) | 6.7 ± 4.0 | 10.8 ± 5.7 | 161 |
| Liver FC (mg g−1 ww) | 3.4 ± 0.5 | 3.3 ± 1.0 | 97.1 |
| Liver CEa (mg g−1 ww) | 0.18 ± 0.09 | 0.48 ± 0.31* | 266 |
| Plasma ALP (U L−1) | 73.4 ± 14.6 | 217 ± 21*** | 296 |
| Plasma AST (U L−1) | 227 ± 108 | 219 ± 56 | 96.5 |
| Plasma ALT (U L−1) | 23.0 ± 4.2 | 51.0 ± 15.4** | 222 |
Values are expressed as means ± SD.
a
Difference between total and free cholesterol.
*
P < 0.05
**
P < 0.01
***
P < 0.001 vs. animals treated with vehicle (unpaired t-test).
ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BW, body weight; CE, cholesterol esters; FC, free cholesterol; TG, triglycerides; ww, wet weight.